5 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18449625 | GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENEIC CELL THERAPY | HASAN, KHALEDA B | 1636 | Final Rejection | Aug 14, 2023 |
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 1632 | Non-Final OA | Apr 13, 2023 |
| 17997103 | REPEAT DOSING OF HYPOIMMUNOGENIC CELLS | HILL, KEVIN KAI | 1638 | Non-Final OA | Oct 25, 2022 |
| 17792121 | MODIFICATION OF BLOOD TYPE ANTIGENS | MCLEOD, AFRICA MHAIRIE | 1635 | Final Rejection | Jul 11, 2022 |
| 17632026 | DUX4 EXPRESSING CELLS AND USES THEREOF | BATES, KEENAN ALEXANDER | 1631 | Final Rejection | Feb 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial